Re-evaluation of treatment options, Quetiapine for Parkinson’s disease psychosis: Dilesh Doshi, PharmD


Watch time: 5 minutes

“Real world evidence on patients using this [pimavanserin] In our daily lives, we are seeing declines in hospitalization rates, emergency room visit rates, and long-term hospitalization rates. These are not clinical symptoms or outcomes, but they do indicate that there are other benefits when psychotic symptoms are resolved. “

Quetiapine is available as a sustained-release or immediate-release tablet and is approved for the adjunctive treatment of schizophrenia, acute manic episodes, and major depressive disorder. This therapy, an atypical antipsychotic, is also used off-label to treat Parkinson’s disease (PD) psychosis. This is a common and troublesome condition in this patient population. A recently published meta-analysis evaluating atypical antipsychotics to treat this condition showed that quetiapine significantly impaired cognition compared to placebo on the Mini-Mental State Examination (standardized mean difference , 0.60; 95% CI, 0.07–1.14).

Pimavanserin (Nuplazid; Acadia Pharmaceuticals) is the only FDA-approved treatment for PD psychosis and Parkinson’s disease psychosis/hallucinations and delusions score (OR, 1.16; 95 %CI, 1.07-1.24). After publication of these data, neurology live® To better understand the results, we spoke with PharmD’s Dilesh Doshi, VP of Health Economics and Outcomes Research at Acadia.

In an interview, Doshi discussed the treatments analyzed in the study and the circumstances under which clinicians should be cautious when prescribing them. He also discussed why pimavanserin’s use has been better understood since it was approved in 2016, and why patients see additional benefits beyond psychotic symptoms.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *